Go Pro
ETR:BAYN

Bayer Aktiengesellschaft (BAYN) Stock Price, News & Analysis

Bayer Aktiengesellschaft logo
€48.05 -0.39 (-0.81%)
As of 07/31/2026

About Bayer Aktiengesellschaft Stock (ETR:BAYN)

Advanced

Key Stats

Today's Range
€47.73
€48.71
50-Day Range
€34.10
€53.36
52-Week Range
€24.96
€44.28
Volume
2.15 million shs
Average Volume
N/A
Market Capitalization
€48.51 billion
P/E Ratio
N/A
Dividend Yield
0.23%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Receive BAYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BAYN Stock News Headlines

A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
Bayer Consolidates U.S. Glyphosate Business Into Ruveon
Bayer stock surges 20% on Supreme Court Roundup ruling
See More Headlines

BAYN Stock Analysis - Frequently Asked Questions

Bayer Aktiengesellschaft's stock was trading at €37.01 at the beginning of the year. Since then, BAYN shares have increased by 29.8% and is now trading at €48.05.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bayer Aktiengesellschaft investors own include Hawkins (HWKN), NVIDIA (NVDA), Meta Platforms (META), Alibaba Group (BABA), Basf (BAS), Volkswagen (VOW3) and Bayerische Motoren Werke Aktiengesellschaft (BMW).

Industry, Sector and Symbol

Stock Exchange
ETR
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
ETR:BAYN
CIK
N/A
Fax
N/A
Employees
96,931
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
(€0.87)
Trailing P/E Ratio
N/A
Forward P/E Ratio
8.90
P/E Growth
36.39
Net Income
-€904.33 million
Net Margins
-4.77%
Pretax Margin
N/A
Return on Equity
-7.52%
Return on Assets
3.71%

Debt

Debt-to-Equity Ratio
134.81
Current Ratio
1.06
Quick Ratio
0.72

Sales & Book Value

Annual Sales
€45.24 billion
Price / Sales
1.07
Cash Flow
€8.39 per share
Price / Cash Flow
5.73
Book Value
€29.48 per share
Price / Book
1.63

Miscellaneous

Outstanding Shares
1,009,583,481
Free Float
N/A
Market Cap
€48.51 billion
Optionable
Not Optionable
Beta
0.83
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (ETR:BAYN) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners